Krystal Biotech
KRYS
NASDAQ
IPO2017
about KRYS
Krystal Biotech is a biopharmaceutical company focused on developing gene therapies to treat rare genetic disorders, particularly inherited corneal diseases, using adeno-associated virus (AAV) vectors for targeted delivery.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $271.27 | $280.54 | $271.27 | $8.0B | 357.32K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$2.74 | n/a | n/a | 42.30% | 81.15% | 0% |